End-of-day quote
Shanghai S.E.
06:00:00 2024-05-19 pm EDT
|
5-day change
|
1st Jan Change
|
23.3
CNY
|
-0.81%
|
|
-3.92%
|
+3.51%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
15,190
|
11,431
|
7,833
|
13,884
|
14,371
|
-
|
-
|
Enterprise Value (EV)
1 |
15,190
|
11,431
|
7,833
|
13,884
|
14,371
|
14,371
|
14,371
|
P/E ratio
|
-70.4
x
|
618
x
|
159
x
|
46.9
x
|
44.8
x
|
51
x
|
43.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
23.2
x
|
12.3
x
|
9.49
x
|
13.7
x
|
11.4
x
|
10.8
x
|
9.42
x
|
EV / Revenue
|
23.2
x
|
12.3
x
|
9.49
x
|
13.7
x
|
11.4
x
|
10.8
x
|
9.42
x
|
EV / EBITDA
|
-227
x
|
175
x
|
49.2
x
|
33.5
x
|
42
x
|
36.4
x
|
33.2
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
3.36
x
|
2.52
x
|
1.7
x
|
2.84
x
|
2.76
x
|
2.62
x
|
2.47
x
|
Nbr of stocks (in thousands)
|
616,211
|
616,211
|
616,786
|
616,786
|
616,786
|
-
|
-
|
Reference price
2 |
24.65
|
18.55
|
12.70
|
22.51
|
23.30
|
23.30
|
23.30
|
Announcement Date
|
2/26/21
|
2/25/22
|
3/21/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
655
|
928.8
|
825.5
|
1,014
|
1,263
|
1,334
|
1,525
|
EBITDA
1 |
-67.05
|
65.39
|
159.4
|
414.3
|
342
|
394.4
|
432.7
|
EBIT
1 |
-188.8
|
-43.63
|
36.94
|
318.2
|
338.8
|
301.2
|
357.4
|
Operating Margin
|
-28.82%
|
-4.7%
|
4.48%
|
31.38%
|
26.83%
|
22.57%
|
23.43%
|
Earnings before Tax (EBT)
1 |
-264.1
|
-53.39
|
28.96
|
310.6
|
331.3
|
293.7
|
349.9
|
Net income
1 |
-200.3
|
18.06
|
49.3
|
294.6
|
319.7
|
281.1
|
331.1
|
Net margin
|
-30.57%
|
1.94%
|
5.97%
|
29.05%
|
25.31%
|
21.07%
|
21.71%
|
EPS
2 |
-0.3500
|
0.0300
|
0.0800
|
0.4800
|
0.5200
|
0.4567
|
0.5367
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/21
|
2/25/22
|
3/21/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-5.54%
|
0.4%
|
1.08%
|
6.2%
|
6.15%
|
5.09%
|
5.66%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
7.340
|
7.370
|
7.470
|
7.940
|
8.440
|
8.890
|
9.430
|
Cash Flow per Share
2 |
-0.0700
|
-0.4100
|
0.3800
|
0.6800
|
-0.0400
|
0.4600
|
0.4200
|
Capex
1 |
227
|
264
|
221
|
135
|
69.5
|
53.3
|
72.1
|
Capex / Sales
|
34.65%
|
28.4%
|
26.76%
|
13.34%
|
5.5%
|
3.99%
|
4.72%
|
Announcement Date
|
2/26/21
|
2/25/22
|
3/21/23
|
2/23/24
|
-
|
-
|
-
|
Last Close Price
23.3
CNY Average target price
32.43
CNY Spread / Average Target +39.18% Consensus |
1st Jan change
|
Capi.
|
---|
| +3.51% | 2.01B | | -2.78% | 90.45B | | +3.95% | 41.45B | | -10.51% | 33.57B | | +60.58% | 25.73B | | -20.09% | 14.73B | | -8.92% | 12.82B | | -11.46% | 11.7B | | -43.05% | 11.44B | | +5.17% | 8.79B |
Biopharmaceuticals
|